Bacteria represents essential class of
micro-organisms that play a crucial role in the development of infection
of any disease to the human being and animal kingdom. Bacteria are
divided into two types on the basis of gram staining test, namely;
gram-positive bacteria and gram-negative bacteria.
Gram-positive bacteria retain the gram stain and
hence are observed as violet purple colored stains when observed under
microscope. These are distinguished from gram-negative bacteria, which
are colored with red stains. Gram-positive bacteria represents the major
class of bacteria and are responsible for infecting humans and animals
with variety of acute and chronic diseases. Gram-positive bacteria are
further divided on the basis of their shapes, such as, cocci and
bacilli.
The Gram-Positive Bacterial Infections Market is
segmented on the basis of various bacteria that belongs to the class,
such as, bacillus, lactobacillus, actinomyces, clostridium,
staphylococcus, streptococcus, listeria, enterococcus, mycobacterium,
and many others. Further, the market is also segmented on the basis of
diseases caused by gram-positive bacteria, such as, tuberculosis and
other respiratory diseases, anthrax, newborn meningitis, acne, and many
others. Moreover, it is segmented on the basis of antibacterial drugs,
such as, B-lactum antibiotics (Penicillin), clavulanic acid (Augmentin),
aminoglycosides (Streptomycin), glycopeptides (Vancomycin),
polypeptides (Bacitracin), rifamycins (Rifampicin), chloramphenicol,
tetracycline and many others.
Additionally, the market is segmented on the basis of
geography, such as, North America, Europe, Asia-Pacific and Rest of the
World (RoW). At present, North America and Europe are the most
prominent markets, owing to growing prevalence of various gram-positive
bacterial infections and associated diseases. However, Asia-Pacific and
some countries in RoW region are expected to show lucrative growth in
upcoming period, owing to rapidly growing prevalence and awareness about
the diseases caused due to gram-positive bacteria and their chronic
effects.
The market is expected to show a prominent growth
during the forecast period 2014 – 2020. This growth is expected to be
driven by factors, such as, increasing prevalence of various gram
positive bacterial infections and extensive R&D practices ongoing
across the globe. These factors are supported by rising awareness about
infections and diseases and increasing medical expenditure. Rising
prevalence of infectious diseases is the most important factor that
drive the growth of the market to a higher end. According to the WHO,
tuberculosis is the second greatest killer across the globe and killed
around 1.3 million people in 2012, throughout the world. Thus, such
infections prevalence is an important growth driver of the market.
Further, due to extensive R&D practices, a number
of drugs and formulations are on the way to enter in the market during
the forecast period 2014 -2020. Some of the important pipeline products
include LTX-109, PYN-6, RX-P792, XF-70, and TD-1607 amongst others. In
addition, various schemes by the WHO, such as, DOTS and Stop TB Strategy
(particular for tuberculosis), helps in increasing awareness amongst
the population, that fuels the growth of the market. On the other hand,
factors such as government austerity, high cost of treatment and
R&D, and ignorance towards the symptoms may hamper the growth of the
market to certain extent.
Some of the major players engaged in R&D and
commercialization of the products in the Gram-Positive Bacterial
Infections market include Basilea Pharmaceuticals Ltd., Cubist
Pharmaceuticals, Novabiotics Ltd., TAXIS Pharmaceuticals, Inc., Aphios Corporation, Pfizer, Inc., GSK plc, Theravance, Inc. amongst many others.
No comments:
Post a Comment